We Empower Precision Medicine

Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY® System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, and clinical research. We are dedicated to enabling clinical laboratories worldwide to deliver affordable targeted genomic testing. Our advanced platform provides timely, accurate, and actionable results, improving clinical decision making and laboratory economics. Agena Bioscience is headquartered in San Diego, CA, and markets its products in over 30 countries worldwide through direct sales offices in Germany, China, and Australia, and through an extensive network of distributors.

www.agenabio.com

Bayer AG is a Life Science company active in the fields of pharmaceuticals and agriculture. With more than 7,000 employees in R&D, Bayer Pharmaceuticals focuses on the development of innovative therapies in Oncology, Cardiovascular Diseases and Women’s Health Care indications and reached 17.962 billion Euros in 2019. The Oncology branch has a diversified portfolio of drugs targeting oncogenic signaling, immune checkpoints as well as radio pharmaceuticals.

Following the motto “Science for a better life”, collaboration with academic and industrial partners is at the heart of Bayer’s R&D approach. The company is involved in multiple projects within the European Public-Private-Partnership Innovative Medicines Initiative (IMI) and held the EFPIA lead for the liquid biopsy technology evaluation consortium CANCER-ID, which is the predecessor of ELBS. Bayer is also part of the International Liquid Biopsy Alliance (ILBA) established by the FNIH.

Bio-Rad is a global leader in a broad range of innovative product categories for life science research and clinical diagnostics that advance the discovery and improve healthcare, including several applications in the liquid biopsy space.

For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification of target molecules. Digital Droplet technology partitions samples into thousands of microfluidic “droplet” test tubes, providing extremely sensitive and accurate digital answers for liquid biopsy research. ddPCR is regarded as the gold standard for orthogonal validation of variant allele frequencies and enables rapid turnaround with lower cost per targeted test.

For assessing CTC phenotype and monitoring tumor prognosis, Celselect Slide™ Technology utilizes the Genesis system to process liquid biopsies for CTC enrichment and enumeration. It can facilitate retrieval of isolated cells to be used in downstream analysis such as single-cell sequencing, FISH or ddPCR. Captured cells can be stained on-slide for scanning on an automated microscope for enumeration. The system is open for users to optimize or develop protocols.

Together, Bio-Rad’s ddPCR and Celselect Slide™ Technologies offer a synergistic and unparalleled degree of insight into both cellular heterogeneity of CTCs as well as the growing to understand their unique biomolecular signatures.

Celselect Slides™ and the Genesis System are for research use only. Not for use in diagnostic procedures.

Exact Sciences has been a global pioneer in detecting cancer earlier and guiding treatment decisions. Today we are a leading, global cancer diagnostics company with over 5.500 employees worldwide. Our common aim is to eradicate cancer -- and the suffering it causes -- with tests that help in preventing cancer, detecting it earlier, and guiding treatment to provide life-changing value to patients.

Building on the success of the Oncotype DX® and the Cologuard® tests, Exact Sciences is investing in its product pipeline to enable personalised care at all stages of the disease.

We serve patients in more than 90 countries and are rapidly building an even stronger international presence to bring our tests to patients around the world.

For more information on Exact Sciences, please visit the company’s website and follow us on Twitter, Facebook or LinkedIn

LGC SeraCare Life Sciences is a leading in vitro diagnostic (IVD) manufacturer of clinical diagnostic quality solutions to the extended life science industry. We are committed to improving patient healthcare by offering products and services that support accurate and reliable diagnostic testing results. These include:

• Quality Controls (IQC), Linearity & Calibration Verification Kits
• Oncology and Reproductive Health Reference Materials
• Proficiency Testing (EQA) Schemes
• Biological Materials, Reagents
• IVD Assay Development
• Quality Assurance Programs

Our 200+ employees and our FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland support diagnostic professionals in laboratories across the globe. We partner with IVD developers, pharmaceutical, CRO and academic institutions to share our expertise and resources in clinical genomics, clinical chemistry, immunochemistry, serology, and molecular diagnostics. LGC SeraCare’s portfolio of Oncology and Reproductive Health -focused reference materials are designed and manufactured to meet the precision challenges of many NGS assays. Our industry reputation and credibility are founded on the high quality ground-truth RNA, ctDNA and genomic DNA-based reference materials which are NGS platform agnostic and used as positive sample controls in tumor profiling, immuno-oncology, liquid biopsy, NIPT and germline cancer assay workflows. We are passionately committed to go beyond. In collaboration with our customers, our people and with absolute quality, we make the exploration of science our mission to create a safer world.

nRichDX® based in Irvine, California, is an emerging leader in preanalytical sample prep solutions for isolation of cfDNA, ctDNA, and other rare analytes. The patented Revolution™ Sample Prep System was engineered specifically for liquid biopsy applications. It is the first and only high-yield, IVD-labeled sample prep platform that can process a wide range of total sample volumes from 1 mL - 50 mL in a single magnetic bead-based extraction from blood, plasma, and urine samples in the company’s unique nRicher™ Cartridge. Unlike other methods, Revolution sample prep doesn’t require sample transfer steps or inefficient sample pooling. nRichDX helps solve one of precision medicine’s greatest problems – – inaccurate or incomplete diagnostic results for liquid biopsy-based molecular diagnostic tests, like NGS and ddPCR, due to insufficient analyte.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The application field of liquid biopsies is one of the key focus areas driving QIAGENs product development initiatives to provide new innovative Sample to insight solutions. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide.

Rarecells Diagnostics aims to improve today’s cancer patient care through the development of highly sensitive and specific blood tests for very early cancer detection and its real time personalized treatment. Rarecells Diagnostics’ technology opens the way to an increased understanding of circulating tumor cells (CTC) biology and of their microenvironment including all types of circulating rare cells. Rarecells Diagnostics’ proprietary disruptive, label-free, liquid biopsy technology ISET® (Isolation by SizE of Tumor cells) isolates from blood and other biological fluids intact CTC of all types of cancers with extremely high sensitivity. The Company also develops and provides protocols and workflows for cyto-molecular profiling of circulating rare cells and their AI-based diagnostic identification. Rarecells Diagnostics is a spin-off of the French Public Institutions: Université Paris Descartes, INSERM (Institut National de la Santé et de la Recherche Médicale) and AP-HP (Assistance Publique- Hôpitaux de Paris), owner of the ISET® patents. Rarecells Diagnostics has the exclusive licenses of the ISET® patents.

RareCyte®, a Seattle-based life sciences company founded in 2010, provides Precision Biology™ solutions for liquid biopsy and highly multiplexed tissue imaging. Our comprehensive product portfolio supports next-generation circulating tumor cell (CTC) characterization, single cell retrieval for molecular analysis, and CTC-based companion diagnostic (CDx) development as well as deep phenotyping and spatial analysis of tissues via 21-plex fluorescence imaging and micro-region sequencing for immuno-oncology and other applications. The RareCyte platform is deployed globally by academic, industry, and pharma services laboratories.

RareCyte enables practical deployment of CTC-based liquid biopsy with instrumentation, reagents, and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation. The RareCyte platform includes AccuCyte® Sample Preparation System, RarePlex® CTC Staining Kits and CyteFinder® Instruments. CTCs and plasma may be analyzed from the same blood collection tube. The highly validated RarePlex® CTC assays allow monitoring of CTC count and investigation of up to two biomarkers, such as ER/HER2 and ARv7/synaptophysin for breast and prostate cancer clinical research respectively. The RareCyte platform incorporates an end-to-end workflow designed for consistent results in multi-site settings common to large clinical research studies. Custom assays may be created using our Developer Kit system and companion diagnostics development is available through our pharma services program.

SAGA Diagnostics is a is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients. The company is commercializing unique technology platforms which are ultrasensitive and can measure circulating tumor DNA (ctDNA) to ~0.001% MAF, which is 100-1000-fold more sensitive and specific than competing methods. Our ultrasensitive technologies are also applicable to conventional tissue biopsies.

SAGAsafe® is a technology platform with patented chemistry which can be run on most dPCR instrument systems. It has its prime utility in detecting and measuring point mutations and indels and can be used to stratify patients, find patients eligible for therapy, monitoring therapy response and MRD, and detection of resistance mutations. The ultrasensitivity means finding more patients earlier. SAGAsafe is currently in a CE-IVD marking process, with the aim of having a menu of clinically relevant assays available for clinical use during 2020-21.

SAGAsign® is a method combining WGS on tumor tissue followed by monitoring ctDNA by personalized dPCR. In an automated fashion, a “fingerprint” of chromosomal rearrangements is selected and a SAGAsign fingerprint assay developed using our proprietary bioinformatics pipeline. We and others have shown chromosomal rearrangements are very stable over time. SAGAsign is ideal for determining tumor burden, monitoring therapy response, detecting MRD, and recurrence monitoring. Research programs and clinical trials benefit from the cost-effectiveness and short turnaround time and SAGAsign’s ultrasensitivity. SAGA is working with academia, hospitals, and biopharma in R&D projects and sells RUO and CE-IVD kits to laboratories.

Tethis S.p.A., a diagnostic company based in Milan, aims to enable the exploitation of liquid biopsy multi-biomarkers analysis in clinical practice for precise cancer management by leveraging on its expertise in sample preparation and processing.

Introducing automation and standardization in the critical pre-analytical phase, Tethis provides the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction). Processing fresh blood in EDTA at the point of blood collection, it ensures the preservation of all clinically relevant information.

The company’s proprietary slides – Smart Bio Surface (SBS), thanks to their functionalized nanocoated surface, allow the spontaneous, immediate, and gentle adhesion of normally non-adherent cells, such as white blood cells (WBCs), with no chemicals, no special temperatures, no other treatment. WBCs adhere to SBS slides as a monolayer distributed on their whole active area. SBS slides, combined with the proprietary automated pre-analytical instrument See.d, allow to identify and characterize rare cells in blood, like CTCs, with unprecedented sensitivity, also in early-stage settings.

See.d prepares in a completely automated and gentle manner SBS slides with fixed WBCs as well as tubes with stabilized plasma without specialized operators nor preservatives: both contents are stable and can be easily stored for efficient logistics (i.e. internal analysis or shipment to central lab). Tethis technology makes both CTCs and cell-free content available for biomarkers detection from the same blood draw, enabling multi-omics applications.

Volition is a leading epigenetics company and aims to revolutionize the diagnosis and monitoring of life-altering diseases, through low-cost routine blood tests.

Our Nucleosomics™ technology isolates any abnormal circulating nucleosomes from the blood bloodstream or other bodily fluid for quantification and analysis.

Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and other diseases. These epigenetic changes can be detected before diseased cells become abnormal enough to show up in traditional biopsies, and long before the first symptoms are felt.

So how will our Nucleosomics™ technology make a difference?

It can be used for population screening, risk stratification, as a diagnostic aid, and for disease and treatment monitoring.

We aim to replace unpleasant, invasive, and often expensive screening and diagnostic tests with Nu.Q® blood tests, helping to save lives and to reduce overall health care costs.

You can use our assays to answer your clinical questions, such as measuring treatment efficacy, or on-target and off-target effects in drug development. Applications include biomarker discovery in oncology, inflammatory conditions, diabetes, and more.

Volition's research and development activities are centred in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.